TY - JOUR
T1 - Clinical Outcomes of Heart Transplant Recipients Admitted with COVID-19 Infection in 2020
T2 - A Nationwide Analysis
AU - Tamimi, Omar
AU - Tamimi, Faisal
AU - Nisar, Tariq
AU - Gaber, Ahmed Osama
AU - Lin, Jiejian
AU - Gorthi, Janardhana
AU - Gotur, Deepa
N1 - Funding Information:
This research was performed using data from the Agency for Healthcare Research and Quality—Healthcare Cost and Utilization Project 2020 National Inpatient Sample dataset. STATA Version 17 produced by Statacorp, LLC in College Station, TX was used for statistical analysis. The content is solely the responsibility of the authors and does not necessarily represent the official views of the Agency for Healthcare Research and Quality nor Statacorp, LLC.
Publisher Copyright:
© 2023 Elsevier Inc.
PY - 2023/12
Y1 - 2023/12
N2 - The COVID-19 pandemic, caused by infection of the SARS-CoV-2 virus, has impacted morbidity and mortality through widespread cytokine release and aberrant immunity; the mainstay of management has been immunosuppression. The aim of our retrospective study is to determine the effects of solid-organ transplantation (SOT) on COVID-19 admissions using data from the 2020 nationwide inpatient sample (NIS). After multivariate adjustment, we found COVID-19 admission with SOT had no difference in mortality (11.5% vs 11.1%, adjusted OR: 0.99 [95% CI 0.84-1.19, P = 0.99], no difference in need for vasopressor use (2.6% vs 1.8%, adjusted OR: 1.02 [95% CI 0.73-1.44, P = 0.88]), lower odds of requiring mechanical ventilation (MV) (13.7% vs 14.8%, adjusted OR: 0.83 [95% CI 0.71-0.97, P = 0.02]), lower odds of MV within 24 hours of admission (adjusted OR: 0.60 [95% CI 0.47-0.78, P < 0.01]), increased odds of mechanical circulatory support needs (adjusted OR 3.7 [95% CI 1.2-11.7, P = 0.025]), increased odds of acute renal failure requiring renal replacement therapy (adjusted OR 1.66 [95% CI 1.29-2.15, P < 0.01]), decreased mean length of stay (7.45 days vs 7.48 days, adjusted difference: 0.8 days less, P <0.01), and no difference in mean total hospitalization charges ($91,316 vs $79,100, adjusted difference: -$2,667, P = 0.57) compared to COVID-19 admissions without SOT.
AB - The COVID-19 pandemic, caused by infection of the SARS-CoV-2 virus, has impacted morbidity and mortality through widespread cytokine release and aberrant immunity; the mainstay of management has been immunosuppression. The aim of our retrospective study is to determine the effects of solid-organ transplantation (SOT) on COVID-19 admissions using data from the 2020 nationwide inpatient sample (NIS). After multivariate adjustment, we found COVID-19 admission with SOT had no difference in mortality (11.5% vs 11.1%, adjusted OR: 0.99 [95% CI 0.84-1.19, P = 0.99], no difference in need for vasopressor use (2.6% vs 1.8%, adjusted OR: 1.02 [95% CI 0.73-1.44, P = 0.88]), lower odds of requiring mechanical ventilation (MV) (13.7% vs 14.8%, adjusted OR: 0.83 [95% CI 0.71-0.97, P = 0.02]), lower odds of MV within 24 hours of admission (adjusted OR: 0.60 [95% CI 0.47-0.78, P < 0.01]), increased odds of mechanical circulatory support needs (adjusted OR 3.7 [95% CI 1.2-11.7, P = 0.025]), increased odds of acute renal failure requiring renal replacement therapy (adjusted OR 1.66 [95% CI 1.29-2.15, P < 0.01]), decreased mean length of stay (7.45 days vs 7.48 days, adjusted difference: 0.8 days less, P <0.01), and no difference in mean total hospitalization charges ($91,316 vs $79,100, adjusted difference: -$2,667, P = 0.57) compared to COVID-19 admissions without SOT.
UR - http://www.scopus.com/inward/record.url?scp=85167781673&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85167781673&partnerID=8YFLogxK
U2 - 10.1016/j.cpcardiol.2023.101996
DO - 10.1016/j.cpcardiol.2023.101996
M3 - Review article
C2 - 37506956
AN - SCOPUS:85167781673
SN - 0146-2806
VL - 48
JO - Current Problems in Cardiology
JF - Current Problems in Cardiology
IS - 12
M1 - 101996
ER -